ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC
March 18, 2025Alphamab Oncology and CSPC jointly announced that anti-HER2 biparatopic ADC JSKN003 has been granted Breakthrough Therapy Designation by the CDE of the NMPA. -
Alphamab Oncology Announces the Study for Ovarian Cancer
February 13, 2025Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003 -
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
December 30, 2024Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE).
Pharma Sources Insight January 2025
